New EpiVax innovation could target Graves’ disease

PROVIDENCE — The first target of immunology engineering biotech firm EpiVax Inc.’s latest antigen-specific therapies? Graves’ disease, an auto-immune condition that results in hypothyroidism. Current therapies not only carry potential side effects, but they can also require lifelong replacement therapy and don’t get at the overall cause of the condition, EpiVax said in a news…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.